Share on StockTwits

Vernalis plc (LON:VER)‘s stock had its “buy” rating reaffirmed by research analysts at Canaccord Genuity in a report released on Monday. They currently have a GBX 52 ($0.89) price objective on the stock. Canaccord Genuity’s price objective suggests a potential upside of 62.37% from the company’s current price.

Vernalis plc (LON:VER) opened at 31.505 on Monday. Vernalis plc has a 52 week low of GBX 18.75 and a 52 week high of GBX 38.00. The stock’s 50-day moving average is GBX 31.72 and its 200-day moving average is GBX 34.63.

A number of other analysts have also recently weighed in on VER. Analysts at N+1 Singer reiterated a “buy” rating on shares of Vernalis plc in a research note on Thursday, June 19th. They now have a GBX 42 ($0.72) price target on the stock. Separately, analysts at Oriel Securities Ltd reiterated a “buy” rating on shares of Vernalis plc in a research note on Thursday, June 19th. They now have a GBX 56 ($0.95) price target on the stock. Finally, analysts at Nplus1 Brewin reiterated a “buy” rating on shares of Vernalis plc in a research note on Thursday, April 24th. They now have a GBX 42 ($0.72) price target on the stock. Five equities research analysts have rated the stock with a buy rating, Vernalis plc presently has an average rating of “Buy” and an average price target of GBX 48 ($0.82).

Vernalis plc is a research and development-stage pharmaceutical company. Vernalis has one marketed product and a portfolio of development and drug discovery programmes.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.